Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases.
Immunovant has raised $550.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in December 2025.
Immunovant's investors include TCG Crossover, Frazier Life Sciences, Frazier Healthcare Partners, Roivant Sciences, Commodore Capital.
Immunovant is headquartered in New York, United States.
Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases.
Immunovant is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Immunovant — Funding & Investors." VCBacked, December 11, 2025, https://www.vcbacked.co/company/immunovant. Accessed September 30, 2026.
VCBacked. (2025). Immunovant — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/immunovant
{{cite web |title=Immunovant — Funding & Investors |url=https://www.vcbacked.co/company/immunovant |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated